Needham & Company LLC Begins Coverage on Kalvista Pharmaceuticals (KALV)

Equities researchers at Needham & Company LLC initiated coverage on shares of Kalvista Pharmaceuticals (NASDAQ:KALV) in a research report issued on Wednesday, The Fly reports. The brokerage set a “buy” rating on the specialty pharmaceutical company’s stock.

Other equities analysts have also issued reports about the stock. BidaskClub lowered shares of Kalvista Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, December 18th. ValuEngine upgraded shares of Kalvista Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, February 4th. Zacks Investment Research lowered shares of Kalvista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 21st. Cantor Fitzgerald restated a “buy” rating and issued a $32.00 price objective on shares of Kalvista Pharmaceuticals in a research report on Friday, December 14th. Finally, TheStreet upgraded shares of Kalvista Pharmaceuticals from a “d+” rating to a “c-” rating in a research report on Thursday, December 20th. Eight research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $27.00.

KALV stock opened at $28.22 on Wednesday. Kalvista Pharmaceuticals has a 12 month low of $7.73 and a 12 month high of $34.92. The company has a market capitalization of $454.12 million, a PE ratio of -18.44 and a beta of 2.45.

Kalvista Pharmaceuticals (NASDAQ:KALV) last released its quarterly earnings data on Thursday, March 14th. The specialty pharmaceutical company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.22. Kalvista Pharmaceuticals had a negative net margin of 70.08% and a negative return on equity of 19.12%. The company had revenue of $3.89 million during the quarter, compared to analyst estimates of $3.97 million. On average, analysts predict that Kalvista Pharmaceuticals will post -1.65 EPS for the current fiscal year.

In related news, major shareholder Svlsf Iv, Llc sold 25,418 shares of the firm’s stock in a transaction that occurred on Monday, December 31st. The shares were sold at an average price of $20.00, for a total value of $508,360.00. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Thomas Andrew Crockett sold 3,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $30.16, for a total transaction of $90,480.00. Following the completion of the sale, the chief executive officer now directly owns 268,510 shares in the company, valued at $8,098,261.60. The disclosure for this sale can be found here. Insiders sold 315,582 shares of company stock valued at $6,557,127 over the last 90 days. 38.40% of the stock is owned by company insiders.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Vivo Capital LLC raised its stake in shares of Kalvista Pharmaceuticals by 352.6% during the third quarter. Vivo Capital LLC now owns 1,359,149 shares of the specialty pharmaceutical company’s stock worth $30,051,000 after acquiring an additional 1,058,824 shares in the last quarter. VHCP Management III LLC purchased a new position in shares of Kalvista Pharmaceuticals during the third quarter worth approximately $28,410,000. VHCP Management II LLC purchased a new position in shares of Kalvista Pharmaceuticals during the third quarter worth approximately $16,785,000. Vanguard Group Inc raised its stake in shares of Kalvista Pharmaceuticals by 152.4% during the third quarter. Vanguard Group Inc now owns 296,581 shares of the specialty pharmaceutical company’s stock worth $6,558,000 after acquiring an additional 179,092 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of Kalvista Pharmaceuticals by 152.4% during the third quarter. Vanguard Group Inc. now owns 296,581 shares of the specialty pharmaceutical company’s stock worth $6,558,000 after acquiring an additional 179,092 shares in the last quarter. 77.31% of the stock is currently owned by institutional investors and hedge funds.

About Kalvista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.

Featured Article: Bull Market

The Fly

Analyst Recommendations for Kalvista Pharmaceuticals (NASDAQ:KALV)

Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit